{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:11:43Z","timestamp":1779109903545,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109099","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:31:40Z","timestamp":1779107500000},"source":"Crossref","is-referenced-by-count":0,"title":["Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study Assessing Metabolic Indices and Microvascular Complications"],"prefix":"10.7759","author":[{"given":"Shubham R","family":"Desale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhransu","family":"Patro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sri","family":"Karlapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouneesh","family":"Karanam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithviraj U","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti Prakash","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/150639","article-title":"Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?","volume":"19","author":"Mitrovic B","year":"2022","unstructured":"Mitrovic B, Gluvic ZM, Obradovic M, Radunovic M, Rizzo M, Banach M, Isenovic ER. Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?. Arch Med Sci. 2022, 19:884-894. 10.5114\/aoms\/150639","journal-title":"Arch Med Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan N","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022, 10:284-296. 10.1016\/S2213-8587(22)00003-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han SK","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023, 29:S5-S16. 10.3350\/cmh.2022.0424","journal-title":"Clin Mol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-1347. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00983-5","article-title":"Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: from pathogenesis to treatment","volume":"20","author":"Yang X","year":"2023","unstructured":"Yang X, Li Q, Liu W, Zong C, Wei L, Shi Y, Han Z. Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023, 20:583-599. 10.1038\/s41423-023-00983-5","journal-title":"Cell Mol Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera V","year":"2023","unstructured":"Ajmera V, Cepin S, Tesfai K, et al.. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023, 78:471-478. 10.1016\/j.jhep.2022.11.010","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13622","article-title":"Mitochondria, oxidative stress and nonalcoholic fatty liver disease: a complex relationship","volume":"52","author":"Karkucinska-Wieckowska A","year":"2022","unstructured":"Karkucinska-Wieckowska A, Simoes IC, Kalinowski P, et al.. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: a complex relationship. Eur J Clin Invest. 2022, 52:e13622. 10.1111\/eci.13622","journal-title":"Eur J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1183808","article-title":"Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis","volume":"10","author":"Zhao YQ","year":"2023","unstructured":"Zhao YQ, Deng XW, Xu GQ, Lin J, Lu HZ, Chen J. Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis. Front Mol Biosci. 2023, 10:1183808. 10.3389\/fmolb.2023.1183808","journal-title":"Front Mol Biosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146962","article-title":"Lipid accumulation and insulin resistance: bridging metabolic dysfunction-associated fatty liver disease and chronic kidney disease","volume":"26","author":"Cao X","year":"2025","unstructured":"Cao X, Wang N, Yang M, Zhang C. Lipid accumulation and insulin resistance: bridging metabolic dysfunction-associated fatty liver disease and chronic kidney disease. Int J Mol Sci. 2025, 26:6962. 10.3390\/ijms26146962","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8463640","article-title":"Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies","volume":"2022","author":"Li G","year":"2022","unstructured":"Li G, Peng Y, Chen Z, Li H, Liu D, Ye X. Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies. Int J Endocrinol. 2022, 2022:8463640. 10.1155\/2022\/8463640","journal-title":"Int J Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10576-z","article-title":"Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study","volume":"18","author":"Shih CI","year":"2024","unstructured":"Shih CI, Wu KT, Hsieh MH, et al.. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int. 2024, 18:138-154. 10.1007\/s12072-023-10576-z","journal-title":"Hepatol Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040968","article-title":"Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes","volume":"11","author":"Mantovani A","year":"2022","unstructured":"Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022, 11:968. 10.3390\/jcm11040968","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1147458","article-title":"Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study","volume":"14","author":"Deravi N","year":"2023","unstructured":"Deravi N, Dehghani Firouzabadi F, Moosaie F, et al.. Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study. Front Endocrinol (Lausanne). 2023, 14:1147458. 10.3389\/fendo.2023.1147458","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17096","article-title":"Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021","volume":"56","author":"Li J","year":"2022","unstructured":"Li J, Ha A, Rui F, et al.. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. Aliment Pharmacol Ther. 2022, 56:396-406. 10.1111\/apt.17096","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa MA","year":"2023","unstructured":"Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2023, 8:660-670. 10.1016\/S2468-1253(23)00066-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo P","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al.. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007, 45:846-854. 10.1002\/hep.21496","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling RK","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006, 43:1317-1325. 10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni G","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6:33. 10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0883","article-title":"METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes","volume":"178","author":"Bello-Chavolla OY","year":"2018","unstructured":"Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, et al.. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018, 178:533-544. 10.1530\/EJE-17-0883","journal-title":"Eur J Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-10765-w","article-title":"Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences","volume":"15","author":"Zhao H","year":"2025","unstructured":"Zhao H, Fang Y, Zhao J, Yang N, Li Y, Liu F, Chen X. Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences. Sci Rep. 2025, 15:24917. 10.1038\/s41598-025-10765-w","journal-title":"Sci Rep"},{"key":"ref21","unstructured":"R. A language and environment for statistical computing, Vienna, Austria. (2020). Accessed: April 24, 2026: http:\/\/www.r-project.org\/."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01902-3","article-title":"Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease","volume":"22","author":"Zou H","year":"2023","unstructured":"Zou H, Ma X, Zhang F, Xie Y. Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease. Lipids Health Dis. 2023, 22:145. 10.1186\/s12944-023-01902-3","journal-title":"Lipids Health Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai Y","year":"2021","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021, 22:4156. 10.3390\/ijms22084156","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase DM","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, et al.. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020, 2020:3920196. 10.1155\/2020\/3920196","journal-title":"J Diabetes Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107 E","year":"2021","unstructured":"Muzurovi\u0107 E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021, 119:154770. 10.1016\/j.metabol.2021.154770","journal-title":"Metabolism"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-23883-x","article-title":"Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD","volume":"25","author":"Zhang J","year":"2025","unstructured":"Zhang J, Li L, Lin L, et al.. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD. BMC Public Health. 2025, 25:2747. 10.1186\/s12889-025-23883-x","journal-title":"BMC Public Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494627-non-alcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes-mellitus-a-cross-sectional-study-assessing-metabolic-indices-and-microvascular-complications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:31:42Z","timestamp":1779107502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494627-non-alcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes-mellitus-a-cross-sectional-study-assessing-metabolic-indices-and-microvascular-complications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.109099","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}